India, July 8 -- ProKidney Corp. (PROK) shares surged 496.87 percent to $3.62 on Tuesday after the company announced positive topline results from its Phase 2 REGEN-007 trial evaluating rilparencel, a potential treatment for chronic kidney disease in patients with diabetes.
Shares opened at $1.27 and traded between $1.02 and $4.45 on the day, with volume spiking to 292.2 million shares, far above the 1.1 million average on the Nasdaq. The stock now trades near its 52-week high of $4.45, after closing at just $0.61 the previous session.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The therapy, which has FDA RMAT designation, showed statistically significant improvements in kidney function, bolsterin...